Last reviewed 2026-08-25
No peptide has been shown to slow human aging or extend human lifespan. Nothing on this page has a longevity outcome trial behind it, because such a trial in humans would take decades and none has been completed. What some of these compounds do have is evidence for specific, narrower effects — better skin appearance, higher measured NAD+ levels, a treatment effect in one rare mitochondrial disease. Those are real, and they are not the same claim.
Longevity is the second most searched goal here, and the hardest to write honestly, because the outcome that matters — living longer or aging more slowly — cannot be measured in the timeframe any of these compounds have existed.
What exists instead are surrogate markers: NAD+ concentration in blood, telomere length, mitochondrial function, skin appearance. Moving a surrogate marker is genuinely interesting and genuinely not the same as slowing aging. Many interventions have moved markers and then failed to change any outcome that mattered.
Read this page as a map of what has actually been measured, and treat any vendor claim about biological age reversal as marketing until someone shows you the endpoint.
Every entry carries the level of human evidence for this use — not the compound’s approval status for something else.
| Peptide | Evidence for this goal | FDA status | Typical cost/mo |
|---|---|---|---|
| Epitalon | Limited human data | Research | $150–$400 |
| NAD+ | Limited human data | Research | $200–$800 |
| SS-31 (Elamipretide) | Human trials, not approved for this use | FDA-approved | $500–$1200 |
| GHK-Cu | Human trials, not approved for this use | Research | $80–$200 |
| MOTS-c | Animal studies only | Research | $200–$500 |
| Sermorelin | No human evidence for this claim | Compounded | $150–$400 |
Sold as a telomerase activator and the flagship 'longevity peptide'.
The catch: The supporting work is almost entirely from a single Russian research group across several decades, and has not been independently replicated to Western trial standards. Treat the lifespan claims with real scepticism.
Coenzyme central to mitochondrial energy metabolism; declines with age.
The catch: Human trials of NAD+ precursors do raise measured NAD+ levels. They have not demonstrated an effect on aging, healthspan, or any hard clinical outcome. Not a peptide, but included because readers look for it here.
Mitochondria-targeting peptide that binds cardiolipin in the inner membrane.
The catch: Has a real clinical development programme and FDA approval in a rare mitochondrial disease. That is a genuine achievement and is not evidence that it slows normal aging.
Copper peptide with well-documented effects on collagen synthesis and skin repair.
The catch: The dermatological evidence is the strongest on this page, but it is about skin appearance and wound repair — a cosmetic and tissue-level effect, not a systemic longevity one.
Mitochondrial-derived peptide linked to metabolic regulation and exercise response.
The catch: Genuinely interesting biology, including associations with longevity in some human population studies. No interventional human trial has tested whether giving it does anything.
Used in anti-aging clinics to raise growth hormone, which declines with age.
The catch: The reasoning is that GH falls with age and restoring it should reverse aging effects. That premise has never been validated, and GH replacement in healthy older adults carries real metabolic risks.
GHK-Cu for skin appearance, where there is real human dermatological data — though that is a cosmetic outcome, not a longevity one. Elamipretide has genuine clinical trial evidence, but in a specific rare disease rather than in aging.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.
Epitalon requires a prescription and medical supervision. Each service below states that a licensed provider reviews your intake and prescribes through a US compounding pharmacy where appropriate. Those are the companies’ own descriptions of how they operate, not findings of ours. Compounded medications are not FDA-approved, and a consultation does not guarantee a prescription.
Some telehealth links below are affiliate links. If you buy through them, we may earn a commission at no extra cost to you. Commission never affects which products or clinics we list, how they are ordered, or what we say about them — see our editorial policy.
Says a board-certified physician reviews each intake and prescribes through a licensed 503A compounding pharmacy where appropriate, and lists a LegitScript certification. Compounded medications are not FDA-approved.
We are not a clinic and do not prescribe. Listing a service here is not a clinical endorsement of it, and you should confirm licensure and pharmacy sourcing yourself before treatment.
None has been shown to slow aging or extend lifespan in humans. Some have evidence for narrower effects — GHK-Cu improves skin appearance in dermatological studies, NAD+ precursors raise measured NAD+ levels — but no compound on this page has a human longevity outcome behind it, because no such trial has been completed.
GHK-Cu has the most robust human evidence, though it is dermatological rather than systemic. Elamipretide has the most rigorous clinical development programme, but it was developed for a rare mitochondrial disease rather than for aging.
The telomerase claims trace back largely to work from a single Russian research group and have not been independently replicated under Western trial standards. Telomere length is also a surrogate marker, so even a real effect on it would not establish a longevity benefit.
Our directory lists clinics whose own websites show they offer peptide therapy. We verify what each one actually provides rather than taking a listing at face value.
Browse the provider directory